Encapsulate
Founded 2019 · 16 employees on LinkedIn · 2 known investors
Encapsulate builds automated tumor-on-a-chip systems that test microtumors derived from patient biopsies against treatment regimens to predict how individual cancer patients will respond, delivering personalized insights in under seven days. It serves oncologists, pharmaceutical companies, and cancer researchers, drawing on a patient biobank for drug testing, patient stratification, and mechanism studies.
Founders & leadership
Encapsulate was founded in 2019 by Armin Rad, Leila Daneshmandi, and Armin Rad, Ph.D..
Investors · 2
Competitors · 1
by search overlapCompanies competing with Encapsulate for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase I | 2022 | $256K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Encapsulate do?
- Encapsulate builds automated tumor-on-a-chip systems that test microtumors derived from patient biopsies against treatment regimens to predict how individual cancer patients will respond, delivering personalized insights in under seven days. It serves oncologists, pharmaceutical companies, and cancer researchers, drawing on a patient biobank for drug testing, patient stratification, and mechanism studies.
- Who founded Encapsulate?
- Encapsulate was founded by Armin Rad, Leila Daneshmandi, Armin Rad, Ph.D. in 2019.
- Who are Encapsulate's investors?
- Encapsulate's investors include Ambit Health Ventures, Connecticut Innovations.